Copyright © 2002 by the European Society of Cardiology.
Cost-effectiveness of an invasive strategy in unstable coronary artery disease. Results from the FRISC II invasive trial
a Institution of Medicine and Care, Linköping University, Sweden
b Center for Medical Technology Assessment, Linköping University, Sweden
Received March 9, 2001; accepted March 21, 2001
Abstract
Aims The utilization and timing of revascularization in unstable coronary artery disease varies, which could have important consequences for patients and for treatment costs. The FRISC II invasive trial compared an early invasive strategy vs a non-invasive strategy with respect to the composite end-point of death and myocardial infarction as well as costs.
Methods and Results A total of 2457 patients, median age 66 years, comprising 70% men, were randomized. We prospectively recorded the patients' use of the health service. The results were analysed in a societal perspective. There was a significant 1·7% absolute reduction in deaths and a 3·7% absolute reduction in deaths and myocardial infarctions in the invasive compared to the non-invasive group after 12 months. During the initial hospitalization a patient in the invasive group spent on average 3·9 more days in hospital than a patient in the non-invasive group. Opposite results were found for rehospitalizations. The difference in mean total costs is SEK 23 876 (P<0·001). The incermental cost-effective ratio for choosing the invasive instead of the non-invasive strategy is SEK 1 404 000 per avoided death and SEK 645 000 per avoided death or myocardial infarction
Conclusion The high cost at the beginning of the invasive strategy is substantial. The clinical results of the FRISC II study provided evidence that the invasive strategy reduces the rate of death and myocardial infarction in patients with unstable coronary artery disease. For policy discussions concerning whether or not to implement the invasive strategy, these positive results should be balanced against the cost-consequences of the strategy.
Key Words: Unstable angina, non-Q wave myocardial infarction, unstable coronary artery disease, costs, cost-effectiveness, revascularization
f1 Correspondence: Magnus Janzon, MD, Department of Cardiology, Linköping Heart Center, University Hospital, SE-581 85 Linköping, Sweden.
References
- National Board of Health and Welfare in Sweden, Swedish Medical Information Database, MARS, Medical Access and Result System, 1998
- Luchi RJ, Scott SM, Deupree RH. Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1987;316:977–984[Abstract]
- Anderson HV, Cannon CP, Stone PH. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator vs placebo and early invasive vs early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. 1995;26:1643–1650[Abstract]
- Boden WE, O'Rourke RA, Crawford MH. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. 1998;338:1785–1792
[Abstract/Free Full Text] - McCullough PA, O'Neill WW, Graham M. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine vs angiography in thrombolytic exclusion (MATE) trial. J Am Coll Cardiol. 1998;32:596–605
[Abstract/Free Full Text] - de Feyter PJ, Serruys PW, van den Brand M. Emergency coronary angioplasty in refractory unstable angina. N Engl J Med. 1985;313:342–346[Abstract]
- Yusuf S, Flather M, Pogue J. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. Lancet. 1998;352:507–514[CrossRef][ISI][Medline]
- Unstable Angina: Diagnosis and Management, 1994
- Lancet. 1996;347:561–568[CrossRef][ISI][Medline]
- Cohen M, Demers C, Gurfinkel EP. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337:447–452
[Abstract/Free Full Text] - Campbell RW, Wallentin L, Verheugt FW. Management strategies for a better outcome in unstable coronary artery disease. Clin Cardiol. 1998;21:314–322[ISI][Medline]
- Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 1998;97:1195–1206
[Free Full Text] - N Engl J Med. 1994;330:956–961
[Abstract/Free Full Text] - Lancet. 1997;349:1429–1435[CrossRef][ISI][Medline]
- Serruys PW, de Jaegere P, Kiemeneij F. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331:489–495
[Abstract/Free Full Text] - Lancet. 1998;352:87–92[ISI][Medline]
- Goklaney AK, Murphy JD, Hillegass WB. Abciximab therapy in percutaneous intervention: economic issues in the United States. Eur Heart J. 1998;19:D52–58
- Favaloro RG. Landmarks in the development of coronary artery bypass surgery. Circulation. 1998;98:466–478
[Free Full Text] - Lancet. 1999;354:708–715[CrossRef][ISI][Medline]
- Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet. 2000;356:9–16[CrossRef][ISI][Medline]
- FASS, 1997, Swedish Drug Catalogue, 1997
- The South County Council Cooperation Committee, Sweden, 1997
- Statistical Yearbook of Sweden 2000, 2000
- Statistical Yearbook of Sweden 2001, 2001
- Currency converter, 2001
- Thompson, SG, Barber, JA, How should cost data in pragmatic randomised trials be analysed? Br Med J, 2000, 320, 1197, 200
- Levin, L-
, Janzon, M, Swahn, E, National Guideline, Coronary Artery Disease, Health-Economic Aspects, 2000
- Bäckman, K, Carlsson, P, Karlsson, E, Schmidt, A, The Costs of Heart Disease, 2000, 2
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M Henriksson, D M Epstein, S J Palmer, M J Sculpher, T C Clayton, S J Pocock, R A Henderson, M J Buxton, and K A A Fox The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial Heart, June 1, 2008; 94(6): 717 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Perk and K. Alexanderson Chapter 8. Sick leave due to coronary artery disease or stroke Scand J Public Health, October 1, 2004; 32(63_suppl): 181 - 206. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Prasad, V. Mathew, D. R Holmes Jr., and B. J Gersh Current management of non-ST-segment-elevation acute coronary syndrome: reconciling the results of randomized controlled trials Eur. Heart J., September 1, 2003; 24(17): 1544 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Barrabes, J. Figueras, C. Moure, J. Cortadellas, and J. Soler-Soler Prognostic Value of Lead aVR in Patients With a First Non-ST-Segment Elevation Acute Myocardial Infarction Circulation, August 19, 2003; 108(7): 814 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Janzon, L-A Levin, and E Swahn Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial Heart, March 1, 2003; 89(3): 287 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Mahoney, C. T. Jurkovitz, H. Chu, E. R. Becker, S. Culler, A. S. Kosinski, D. H. Robertson, C. Alexander, S. Nag, J. R. Cook, et al. Cost and Cost-effectiveness of an Early Invasive vs Conservative Strategy for the Treatment of Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction JAMA, October 16, 2002; 288(15): 1851 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Moller Comment concerning 'Cost-effectiveness of an invasive strategy in unstable coronary artery disease' Eur. Heart J., October 2, 2002; 23(20): 1634 - 1634. [Full Text] [PDF]
|
|
|
|
 |
|
 Invasive Strategy for Non-ST-Segment Elevation MI Is Better but Costly Journal Watch Emergency Medicine, February 27, 2002; 2002(227): 9 - 9. [Full Text]
|
|
|
|
|
|
A.P. Davie and J.J.V. McMurray Cost effectiveness of invasive strategy in unstable coronary disease--what are we waiting for? Eur. Heart J., January 1, 2002; 23(1): 1 - 3. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||